Recursion Pharmaceuticals (RXRX) Assets (2020 - 2026)

Recursion Pharmaceuticals has reported Assets for 7 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 2.63% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 2.63% YoY), and the FY2025 full-year result was $1.5 billion, up 1.76% from the prior year.
• Assets for Q1 2026 stood at $1.3 billion, down from $1.5 billion in the prior quarter.
• The five-year high for Assets was $1.5 billion in Q4 2025, with the low at $557.8 million in Q1 2024.
• Historically, Assets has averaged $919.3 million across 5 years, with a median of $726.5 million in 2024.
• Annual changes were most pronounced in 2022 — Assets surged 170.03% — and 2023, when it slipped 14.56%.
• Recursion Pharmaceuticals' Assets stood at $701.3 million in 2022, then dropped by 6.79% to $653.7 million in 2023, then surged by 121.6% to $1.4 billion in 2024, then advanced by 1.76% to $1.5 billion in 2025, then decreased by 9.13% to $1.3 billion in 2026.
• The last three Assets figures came in at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.